Anna Sviridenko
Innsbruck, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Diagnostic Performance of the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: March 10, 2025
Safety, Biodistribution, and Radiation Dosimetry of the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: September 28, 2024
Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer.
Journal: European journal of nuclear medicine and molecular imaging
Published: May 23, 2024
Cholecystokinin-2 receptor targeting by [68Ga]Ga-DOTA-MGS5 PET/CT in a patient with extensive disease small cell lung cancer.
Journal: European journal of nuclear medicine and molecular imaging
Published: March 05, 2024
Enhancing Clinical Diagnosis for Patients With Persistent Pulmonary Abnormalities After COVID-19 Infection: The Potential Benefit of 68 Ga-FAPI PET/CT.
Journal: Clinical nuclear medicine
Published: October 18, 2022
Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: September 29, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026